DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Lenalidomide and its role in the management of multiple myeloma.

Author(s): Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A

Affiliation(s): Divisione di Ematologia dell'Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy.

Publication date & source: 2008-06, Expert Rev Anticancer Ther., 8(6):865-74.

Publication type: Review

Treatment of multiple myeloma has changed in recent years. Advances in the understanding of the pathogenesis of the disease and the mechanism of drug resistance have led to the development of novel effective biological treatment agents such as thalidomide and bortezomib. Lenalidomide is an oral analogue of thalidomide that lacks the neurotoxic side effects associated with the parent drug, and has shown significant antimyeloma activity. Lenalidomide has now been approved by the US FDA and the European Medicines Agency for use in combination with dexamethasone in patients with at least one prior therapy. Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma.

Page last updated: 2008-08-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017